GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports. They currently have a $18.00 price objective on the stock.

GOVX has been the subject of several other research reports. Alliance Global Partners started coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They issued a “buy” rating and a $15.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $14.20.

GeoVax Labs Price Performance

Shares of GOVX opened at $1.91 on Friday. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18. The business’s 50 day simple moving average is $2.33 and its 200-day simple moving average is $2.74.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same period in the prior year, the firm posted ($4.80) EPS. On average, sell-side analysts predict that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC bought a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.